<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04246632</url>
  </required_header>
  <id_info>
    <org_study_id>CLN-CVI-5248</org_study_id>
    <nct_id>NCT04246632</nct_id>
  </id_info>
  <brief_title>CapsoCam® Colon Capsule Endoscope (CCE) Compared to Colonoscopy (OC)</brief_title>
  <official_title>Prospective, Open Label, Pilot Study of the CapsoCam® Colon Capsule Endoscope (CCE) Compared to Colonoscopy (OC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capso Vision, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capso Vision, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This non-significant risk pilot study is designed to evaluate safety and performance of the&#xD;
      CapsoCam® Colon capsule endoscope in patients who meet the eligibility criteria and are&#xD;
      scheduled for colonoscopy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 25, 2020</start_date>
  <completion_date type="Actual">March 15, 2021</completion_date>
  <primary_completion_date type="Actual">February 25, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Multi-Center; Prospective, Open Label, Non-Significant Risk, Pilot Study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>PI is masked to Capsule results and capsule reader is masked to colonoscopy results.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy Assessments</measure>
    <time_frame>Day 1</time_frame>
    <description>Determine the Accuracy of CapsoCam® to detect and measure size of colon polyps relative to the colonoscopy procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Assessments: Incidence of device related serious adverse events (SAEs) and unanticipated adverse device effects (UADEs)</measure>
    <time_frame>Day 1-3</time_frame>
    <description>All adverse events including SAEs/UADEs will be assessed at all visits. Incidence of serious adverse events (SAEs) and unanticipated adverse device effects (UADEs) will be reported. A serious adverse event is one that meets the definition outlined in Section 8 of this protocol.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Colonoscopy</condition>
  <arm_group>
    <arm_group_label>Open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm study, all subjects receive device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CapsoCam Colon Capsule Endoscopy</intervention_name>
    <description>CapsoCam® Colon is intended to provide visualization of the colon and the detection of colon polyps in adults.</description>
    <arm_group_label>Open label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Between the ages of 50 and 75 years old&#xD;
&#xD;
          2. Subject meets at least one of the following criteria for increased risk for polyps:&#xD;
&#xD;
               1. Recent history (within 6 months) of positive FIT/iFOBT or Cologuard test&#xD;
&#xD;
               2. Older than 55 years of age, without prior history of colonoscopy&#xD;
&#xD;
               3. Has had a positive colonoscopy ≥ 5 years prior to screening visit&#xD;
&#xD;
               4. And/or having at least two of the following risk factors:&#xD;
&#xD;
                    -  Current smoker&#xD;
&#xD;
                    -  BMI of ≥30&#xD;
&#xD;
                    -  Family history (blood relative) of colorectal cancer&#xD;
&#xD;
                    -  Sedentary lifestyle&#xD;
&#xD;
                    -  Low fiber/ high fat diet&#xD;
&#xD;
          3. No contraindication for capsule endoscopy or colonoscopy&#xD;
&#xD;
          4. Committed to undergo a colonoscopy, independent of this study within 8 weeks of&#xD;
             Capsule ingestion&#xD;
&#xD;
          5. Choose to participate and must have signed the IRB-approved informed-consent document&#xD;
             and agreed to release colonoscopy images and results report to Sponsor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of negative colonoscopy within the last 10 years&#xD;
&#xD;
          2. History of incomplete colonoscopy&#xD;
&#xD;
          3. Impaired cardiac function assessed as greater than NYHA Class II&#xD;
&#xD;
          4. History of small- or large-bowel obstructive condition&#xD;
&#xD;
          5. Known history of Crohn's disease, swallowing disorder, ulcerative colitis, ischemic&#xD;
             bowel disease and/or radiation enteritis&#xD;
&#xD;
          6. Known history of NSAID enteropathy and stricture resulting from taking NSAIDs on a&#xD;
             regular basis that, in the opinion of the Investigator, would put the patient at&#xD;
             greater risk for capsule endoscope retention&#xD;
&#xD;
          7. Unable to follow or tolerate fasting, bowel preparation, and other study procedures&#xD;
&#xD;
          8. Known allergy to ingredients used in bowel preparation and boosters&#xD;
&#xD;
          9. Daily and/or regular use of narcotics&#xD;
&#xD;
         10. Known or suspected AIDS&#xD;
&#xD;
         11. Uncompensated cirrhosis&#xD;
&#xD;
         12. Prior abdominal radiation therapy&#xD;
&#xD;
         13. Diagnosis of anorexia or bulimia&#xD;
&#xD;
         14. History of or suspicion for: strictures, volvulus or intestinal obstruction; internal&#xD;
             hernias or abdominal surgeries that the Investigator considers as an exclusion&#xD;
&#xD;
         15. Known or suspected megacolon&#xD;
&#xD;
         16. Scheduled to undergo MRI examination within 7 days after ingestion of the capsule&#xD;
&#xD;
         17. Has known slow gastric-emptying time or confirmed diagnosis of gastroparesis&#xD;
&#xD;
         18. Pregnant or nursing or is of child-bearing potential and does not practice medically&#xD;
             acceptable methods of contraception. Women of childbearing potential (WOCBP) must have&#xD;
             a negative urine pregnancy test at screening.&#xD;
&#xD;
         19. Any documented medical or psychological condition or significant concurrent illness&#xD;
             which, in the Investigator's opinion, would make it unsafe for the subject to&#xD;
             participate in this research study&#xD;
&#xD;
         20. Are currently enrolled in, or participated in within the last 30 days, another&#xD;
             clinical study&#xD;
&#xD;
         21. Chronic constipation as defined by &lt;3 bowel movements per week for at least 3 months&#xD;
             prior to Screening, or the use of routine laxatives (other than fiber) to attain r&#xD;
             regular bowel movements for at least 3 months prior to Screening&#xD;
&#xD;
         22. History of diabetes in which the prolonged fasting schedule could impose additional&#xD;
             safety risks, as determined by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Silicon Valley Research Institute, Inc.</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CapsoVision Research Clinic</name>
      <address>
        <city>Saratoga</city>
        <state>California</state>
        <zip>95070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Michigan Clinical Research Center</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 24, 2020</study_first_submitted>
  <study_first_submitted_qc>January 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2020</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All IPD will be kept confidential. Safety events/concerns will be shared will all sites without exposing PHI.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

